Introduction

The Doxotor 10 mg (Doxorubicin) Injection is a potent anthracycline chemotherapy agent used to treat advanced ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma. Manufactured by Eskayef Pharmaceuticals Ltd., a leader in oncology innovation, and supplied globally by Onco Solution, this injection disrupts cancer cell proliferation by inhibiting DNA synthesis and topoisomerase II activity. With its proven efficacy in refractory cancers, the Doxotor 10 mg (Doxorubicin) Injection offers hope for patients who have exhausted prior therapies.

Key Benefits

• Targeted DNA Disruption: Inhibits nucleic acid synthesis by intercalating with DNA, halting tumor growth.
• Versatile Application: Effective for ovarian cancer, Kaposi’s sarcoma, and multiple myeloma.
• Combination Synergy: Enhances outcomes when paired with bortezomib for myeloma treatment.
• Global Accessibility: Supplied by Onco Solution, ensuring reliable access to life-saving therapies.

Indications

The Doxotor 10 mg (Doxorubicin) Injection is indicated for:

1. Ovarian Cancer: After failure of platinum-based chemotherapy.
2. AIDS-Related Kaposi’s Sarcoma: Post-failure of prior systemic chemotherapy.
3. Multiple Myeloma: Combined with bortezomib in patients who have received ≥1 prior therapy.

Pharmacology

• Mechanism of Action: Doxorubicin, the active ingredient, binds to DNA and inhibits topoisomerase II, disrupting replication and transcription. This leads to apoptosis in rapidly dividing cancer cells.
• Cytotoxic Spectrum: Demonstrates activity against a wide range of malignancies, including solid tumors and hematologic cancers.

Dosage & Administration

• General Guidelines:
  • Administer intravenously at an initial rate of 1 mg/min to minimize infusion reactions. If tolerated, complete infusion over 1 hour.
  • Do not administer as a bolus or undiluted solution.
• Dosing by Indication:
  • Ovarian Cancer: 50 mg/m² every 4 weeks.
  • Kaposi’s Sarcoma: 20 mg/m² every 3 weeks.
  • Multiple Myeloma: 30 mg/m² on day 4 post-bortezomib.

Drug Interactions

• Antibiotics: Increased nephrotoxicity risk with aminoglycosides.
• Steroids/Aminophylline: Potential for enhanced toxicity.
• Propranolol: Altered pharmacokinetics; monitor closely.

Contraindications

• Severe cardiac disease or prior mediastinal irradiation.
• Pregnancy, lactation, or neonatal use.
• Severe myelosuppression from prior chemotherapy/radiotherapy.

Side Effects

Common Reactions:

• Hematologic: Leukopenia, thrombocytopenia.
• Gastrointestinal: Nausea, vomiting, diarrhea.
• Dermatologic: Alopecia, skin pigmentation.

Serious Risks:

• Cardiotoxicity: Cumulative dose-dependent cardiomyopathy (monitor LVEF).
• Neurotoxicity: Seizures, confusion, peripheral neuropathy.
• Hypersensitivity: Facial flushing, rash (premedicate with antihistamines).

Pregnancy & Lactation

• Pregnancy Category D: Contraindicated except in life-threatening scenarios.
• Lactation: Discontinue breastfeeding due to infant toxicity risks.

Precautions & Warnings

• Hepatic Impairment:
  • Bilirubin 12–30 mcg/mL: Reduce dose by 50%.
  • Bilirubin >30 mcg/mL: Reduce dose by 75%.
• Cardiac Monitoring: Regular ECGs and echocardiograms for patients with risk factors.
• Myelosuppression: Monitor CBC weekly; delay therapy if neutrophils <1,500 cells/mm³.

Overdose Management

• Symptoms: Severe mucositis, myelosuppression, cardiomyopathy.
• Treatment:
  • Hospitalize for supportive care (antibiotics, platelet transfusions).
  • Administer G-CSF/GM-CSF for neutropenia.
  • Manage heart failure with diuretics, ACE inhibitors.

Storage Conditions

• Powder for Injection: Store at 15–30°C.
• Solution/Liposomal Formulations: Refrigerate at 2–8°C; avoid freezing.

Why Choose Doxotor 10 mg (Doxorubicin) Injection?

• Trusted Quality: Produced by Eskayef Pharmaceuticals Ltd., a WHO-GMP-certified manufacturer with 30+ years of oncology expertise.
• Global Supply Chain: Supplied by Onco Solution, ensuring timely access across Asia, Africa, and Europe.
• Clinical Validation: Proven efficacy in regressing advanced malignancies while balancing tolerability.

Conclusion

The Doxotor 10 mg (Doxorubicin) Injection is a cornerstone of advanced cancer therapy, offering targeted DNA disruption for ovarian cancer, Kaposi’s sarcoma, and myeloma. By integrating this anthracycline into treatment regimens, clinicians leverage a trusted solution backed by Eskayef Pharmaceuticals Ltd.’s rigorous standards and Onco Solution’s global reach.